EGFR and breast cancer: Recent preclinical and clinical successes include a combination of doxorubicin with erlotonib in non-small cell lung cancer and breast cancer as well as the use of synthesized PARP and EGFR inhibitors utilized in combination with adriamycin (doxorubicin) against various cancer cell lines, including MCF-7 and TNBC [30,31].